Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

TCR2 THERAPEUTICS INC.

(TCRR)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur TCR2 THERAPEUTICS INC.
22/11TCR2 Therapeutics Inc. Announces Resignation of Mayur Somaiya, Effective December 10, 2..
11/11Tcr-2 therapeutics reports third quarter 2021 financial results and provides corporate ..
10/11TCR2 THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
10/11TCR2 Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate U..
10/11TCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate U..
10/11TCR2 Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
01/11TCR2 Therapeutics Announces Expansion of U.S. Manufacturing Capacity - Form 8-K
01/11TCR2 THERAPEUTICS INC. : Costs Associated with Exit or Disposal Activities, Financial Stat..
01/11TCR² Therapeutics Announces Expansion of U.S. Manufacturing Capacity
01/11Tcr2 Therapeutics Inc. Announces Expansion of U.S. Manufacturing Capacity
26/10TCR2 Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers S..
26/10TCR2 THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
26/10Tcr-2 therapeutics announces clinical trial collaboration agreement with bristol myers ..
25/10TCR2 THERAPEUTICS : Initiates Clinical Trial Partnership With Bristol Myers Squibb to Eval..
25/10BRISTOL MYERS SQUIBB : TCR² Therapeutics Announces Clinical Trial Collaboration Agreement ..
22/10TCR2 THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
22/10NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
21/10TCR2 THERAPEUTICS : Tcr-2 therapeutics reviews pipeline and strategy at r&d day
20/10TCR2 THERAPEUTICS : Press release issued by TCR2 Therapeutics Inc. on October 20, 2021 - F..
20/10TCR2 THERAPEUTICS INC. : Regulation FD Disclosure, Other Events, Financial Statements and ..
20/10TCR2 THERAPEUTICS : TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day
20/10TCR2 Therapeutics Inc. Reviews Pipeline and Strategy At R&D Day
14/10TCR2 THERAPEUTICS : Tcr-2 therapeutics to host r&d day on october 20, 2021
13/10TCR2 THERAPEUTICS : TCR² Therapeutics to Host R&D Day on October 20, 2021
06/10TCR2 THERAPEUTICS : Tcr-2 therapeutics presents preclinical data on il-15 enhanced trucs a..
05/10TCR2 THERAPEUTICS : TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at..
05/10TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Spe..
20/09TCR2 THERAPEUTICS : Tcr-2 therapeutics announces positive interim results from ongoing pha..
17/09TCR2 THERAPEUTICS : Must Arrange Additional Trials For Solid Tumors Treatment to Support E..
17/09TCR2 THERAPEUTICS : Tumble Following Interim Results From Trial of Gavo-cel to Treat Solid..
17/09NASDAQ 100 : Top Midday Decliners
17/09TCR2 THERAPEUTICS : Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gav..
17/09TCR2 THERAPEUTICS INC. : Regulation FD Disclosure, Other Events, Financial Statements and ..
17/09TCR2 THERAPEUTICS : Reports Interim Result From Phase 1/2 Trial of Gavo-cel to Treat Solid..
17/09TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Ga..
17/09TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Ga..
13/09TCR2 THERAPEUTICS : to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel ..
08/09TCR2 THERAPEUTICS : Tcr-2 therapeutics to present at the h.c. wainwright global investment..
07/09TCR2 THERAPEUTICS : TCR² Therapeutics to Present at the H.C. Wainwright Global Investment ..
03/09TCR2 THERAPEUTICS : Tcr-2 therapeutics receives fda orphan drug designation for gavo-cel f..
02/09TCR2 THERAPEUTICS : Receives FDA Orphan Drug Designation for Gavo-Cel; Shares Rise Early
02/09TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment o..
02/09TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-Cel for the Treatment o..
02/09TCR Therapeutics Gets FDA Orphan Designation for Gavo-cel in Bile-Duct Cancer
27/08TCR2 THERAPEUTICS : Tcr-2 therapeutics announces renowned translational medicine leader pr..
27/08TCR2 THERAPEUTICS : Announces Renowned Translational Medicine Leader Priti Hegde Joins Its..
26/08TCR2 THERAPEUTICS INC. : Change in Directors or Principal Officers, Financial Statements a..
26/08TCR2 THERAPEUTICS : TCR² Therapeutics Announces Renowned Translational Medicine Leader Pri..
26/08TCR2 Therapeutics Inc. Announces Board Changes
18/08TCR2 THERAPEUTICS : Tcr-2 therapeutics announces upcoming medical meetings update
17/08TCR2 THERAPEUTICS : TCR² Therapeutics Announces Upcoming Medical Meetings Update
06/08TCR2 THERAPEUTICS : Tcr-2 therapeutics reports second quarter 2021 financial results and p..
05/08TCR2 THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result..
05/08TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate ..
05/08Tcr2 Therapeutics Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2..
21/07TCR2 THERAPEUTICS : Tcr-2 therapeutics appoints cell & gene therapy manufacturing veteran ..
20/07TCR2 THERAPEUTICS : TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing Veteran P..
20/07TCR² Therapeutics Appoints Peter Olagunju as Chief Technical Officer
25/06TCR2 THERAPEUTICS INC.(NASDAQGS : TCRR) dropped from Russell 3000E Growth Index
25/06TCR2 THERAPEUTICS INC.(NASDAQGS : TCRR) dropped from Russell Microcap Growth Index
25/06TCR2 THERAPEUTICS INC.(NASDAQGS : TCRR) dropped from Russell Small Cap Comp Growth Index
25/06TCR2 THERAPEUTICS INC.(NASDAQGS : TCRR) dropped from Russell 2500 Growth Index
25/06TCR2 THERAPEUTICS INC.(NASDAQGS : TCRR) dropped from Russell 3000 Growth Index
25/06TCR2 THERAPEUTICS INC.(NASDAQGS : TCRR) dropped from Russell 2000 Growth Index
27/05TCR2 THERAPEUTICS : Tcr-2 therapeutics to participate in two upcoming conferences in june
26/05TCR² Therapeutics to Participate in Two Upcoming Conferences in June
14/05TCR2 THERAPEUTICS : Reports First Quarter 2021 Financial Results and Provides Corporate Up..
14/05TCR2 THERAPEUTICS : Tcr-2 therapeutics reports first quarter 2021 financial results and pr..
13/05TCR2 THERAPEUTICS : Q1 Loss Shrinks
13/05TCR2 THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result..
13/05Tcr2 Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2..
13/05TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate U..
30/04TCR2 THERAPEUTICS : Securities Registered under Registration Statement on Form S-3
30/04TCR2 THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
30/04TCR2 THERAPEUTICS : TCR-2 Therapeutics to Present at the Truist Securities Life Sciences S..
1  2  3  4Suiv.
Prochain événement sur TCR2 THERAPEUTICS INC.